Global Liquid Biopsy Market Report by Product, Application, Cancer Type, Circulating Biomarker, End Users, Countries and Companies Analysis 2026-2034

Global Liquid Biopsy Market Size & Forecast 2026-2034

The liquid biopsy market is expected to grow from US$ 2.83 billion in 2025 to US$ 5.49 billion by 2034, at a CAGR of 7.63% from 2026 to 2034. A key factor contributing to the growth of the market is the increasing demand for non-invasive cancer diagnostics, along with the growing prevalence of cancer. Advancement in genomic and molecular testing technologies further assists in market growth. Growing adoption in early detection, treatment monitoring, and personalized medicine further supports market expansion.

Liquid Biopsy Market Outlook

Liquid biopsy is a less invasive testing methodology for the detection and characterization of biomarkers like circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other forms of nucleic acids in body fluids like blood. Unlike biopsies, the process of liquid biopsy does not involve any invasive surgery and can be carried out multiple times with ease and with less discomfort for the patient. The technique has been extensively used in the field of cancer for the diagnosis and monitoring of the progress of the disease and for determining the sensitivity of the tumor to treatments and therapies.

Globally, liquid biopsy has attracted immense attention for its medical benefits and developments in the field. The increasing incidence of cancers and the importance of earlier diagnosis have further fueled the demand for liquid biopsy. Healthcare professionals and researchers are appreciative of the capacity of liquid biopsy to monitor the development of cancer and the possibility of detecting recurrence at an earlier stage than has been possible in the past. The development of next-generation sequencing has further enhanced the precision of liquid biopsy.

Growth Driver in the Global Liquid Biopsy Market

Rising Prevalence of Cancer and Demand for Early Diagnosis

The increasing global prevalence of cancer is one of the major growth drivers of the liquid biopsy market. It remains one of the leading causes of mortality worldwide, thus provoking high demand for diagnostic solutions that are early, accurate, and less invasive. Liquid biopsy allowed for the identification of cancer biomarkers such as mutations and gene expression changes in the early beginning of the disease, and many times prior to the appearance of symptoms. It would improve clinical benefits through better treatment outcomes and survival rates. The liquid biopsy does not have all restrictions associated with traditional tissue biopsies since it can be done repeatedly, and continuous monitoring of disease conditions and response to treatments is possible. Indeed, growing awareness among clinicians and patients about the benefits accrued from early detection and real-time monitoring contributes to accelerating the pace of adoption. In 2025, there will be an estimated 2,041,910 new cases diagnosed and 618,120 deaths from this disease in the United States alone. The most common cancers include breast, prostate, lung and bronchus, colon and rectum, melanoma of the skin, bladder, kidney and renal pelvis, non-Hodgkin lymphoma, uterine corpus, pancreatic, leukemia, thyroid, and liver and intrahepatic bile duct cancer.

Advancements in Genomic and Molecular Diagnostic Technologies

The increasing pace of advances in genomic sequencing and molecular testing is another major driver for the market. New advancements in next-generation sequencing, digital PCR, and bioinformatics are enhancing the ability to precisely and reliably test for cancers through liquid biopsies. Such technologies are capable of identifying low-frequency mutations and tumor heterogeneity in cancers. R&D investments by biotechs are increasing their ability to test for multiple types of cancers through their innovative technologies. April 2025, Labcorp announced the expansion of its precision oncology offerings with two new tests. The first new addition to its offerings is Labcorp Plasma Detect. The test is designed to support the assessment of post-surgery relapse risk for patients with stage III colon cancer. The test will add to its diagnostic capabilities to identify eligible patients for targeted therapy. PGDx elio plasma focus Dx is another innovative test added to its offerings. They are actually the first and only FDA-approved prepared liquid biopsy test for solid cancers and support its ability to imply eligible patients for targeted therapy.

Growing Adoption of Personalized and Precision Medicine

Personalized and precision medicine is fueling the market for liquid biopsies. A liquid biopsy enables personalized treatment by detecting unique genetic mutations and markers that determine targeted treatment options for a patient. Liquid biopsies have also become a common practice for oncologists to determine treatment efficacy and identify early markers of treatment resistance for cancer treatment. The pharmaceutical industry also employs liquid biopsies for developing new treatments and clinical trials by enabling them to categorize and tailor treatments for their patients. Moreover, with precision medicine becoming more and more a part of cancer treatment and care, the demand for liquid biopsies is increasing at a rapid pace. In April 2025, a leading company for precision oncology solutions, Guardant Health, announced a strategic partnership with Bayshore HealthCare, a home and community healthcare group and one of the largest healthcare providers in Canada. Under this partnership, Guardant Health's entire range of precision oncology solutions would now be accessible through Bayshore HealthCare's nationwide network of clinics and would support patients along the entire cancer healthcare continuum within Canada.

Challenge in the Global Liquid Biopsy Market

High Cost and Limited Accessibility

High costs involved with the accessibility of liquid biopsy tests are one of the major hurdles hindering the growth of this market. The costs involved with advanced technology, equipment, as well as the expertise required for these tests, make them less accessible to developing countries. However, lack of reimbursement from governments for these tests is another aspect that is hindering their adoption.

Regulatory Complexity and Clinical Validation

The challenges in the market for liquid biopsies include regulatory complexity and the need for comprehensive validation of liquid biopsies in clinical settings. The regulatory bodies need concrete proof of accuracy, reliability, and clinical usefulness of the liquid biopsies before they can authorise their use in the market. The need for wide-scale clinical trials of liquid biopsies is a time-consuming process that is very expensive too.

Liquid Biopsy Kits & Reagents Market

The kits and reagents for liquid biopsies are essentially driving the market for liquid biopsies as these kits include necessary components for the preparation of samples for analysis. These kits are required for the isolation of tumor DNA, RNA, and tumor cells from patient blood and other body fluids. Rising adoption of these kits due to their ability to ensure simple and accurate testing is accelerating. Liquid biopsy testing, being increasingly adopted for various applications in oncology, will see growing adoption of kits and reagents. Research and diagnostic labs Demand for ready-to-use kits and reagents will ensure higher-quality results. Rising adoption for research purposes will drive this market.

Cancer Therapeutic Liquid Biopsy Market

The cancer therapeutic liquid biopsy market is primarily concerned with leveraging the potential of liquid biopsy to inform and track cancer treatment. The technology essentially helps in evaluating the presence of actionable genomic alterations, choosing appropriate target drugs, and assessing the response to treatment in real time. There is increasing reliance on liquid biopsy in the medical field to detect resistance to drugs as well as the progression of the disease ahead of imaging and biopsy. The industry also applies the concept of liquid biopsy in its research and development activities to categorize patients appropriately.

Liquid Biopsy Circulating Tumour Cell Market

The liquid biopsy circulating tumor cell market is primarily based on the detection and analysis of whole tumor cells that are released into the bloodstream. Analyzing CTCs offers immense knowledge regarding tumor biology, metastasis, as well as the progress of cancer. Although difficult because the number of these cells is low, innovations in capturing and analyzing tools are making this process easier. Liquid biopsy based on CTCs is highly helpful for understanding metastasis as well as the efficacy of therapies. Scientific interest for research on CTCs is quite high, with clinical applications expanding gradually.

Liquid Biopsy Diagnostic Laboratories Market

The diagnostic laboratories market for liquid biopsy is a significant market, not only increasing with higher testing volume but also with adoption. Specialized diagnostic laboratories conduct liquid biopsy for cancer, diagnosis, management, and treatment decision-making. The diagnostic labs have invested heavily in advanced sequencing systems, automation, and bioinformatics for precise testing. The diagnostic labs have the advantage of scalability and economy with centrally located labs, thereby increasing accessibility. The rise in partnership with hospitals and cancer specialists has further aided the market. The diagnostic labs play an integral part with increasing adoption of liquid biopsy for cancer management.

Liquid Biopsy Academic Institutes Market

The market for academic institutes for liquid biopsy is primarily involved with research and development work for enhancing technology and applications. The main area of research for universities or research institutes involves new biomarkers, new technologies for detection, as well as clinical validity. The innovations brought about by research in academic institutes form the foundation for commercialization, as scientific evidence is required for new technologies. Financing for numerous researches is provided by government or other organizations, which helps the market for the immense research being done in the aspect of liquid biopsy.

United States Liquid Biopsy Market

The United States has the most sophisticated market for liquid biopsy, due to their robust healthcare infrastructure, prevalent cancer cases, and adoption of innovative diagnostic solutions right from the outset. Presence of renowned biotech firms, diagnostic labs, and research institutions spurs the development and launches of liquid biopsy solutions sooner rather than later. Precision medicine and targeted oncology have received prominence, which facilitates broader adoption in cancer diagnosis in the early stages, during treatment assessment, and in recurrence testing. Favorable regulatory and increased reimbursements for certain types of liquid biopsy solutions pave the way for adoption as well. The pharmaceutical industry relies heavily on liquid biopsy solutions in their clinical studies and development of new treatments as well. In January 2023, Tempus AI, Inc. launched its newly approved in vitro diagnostic test based on next-generation sequencing (NGS), 'xT CDx.' This in-vitro test will be made available for all ordering physicians in the U.S. market as well.

Germany Liquid Biopsy Market

The strong healthcare system, advanced diagnostic infrastructure, and high awareness for the early detection of cancer are driving factors for the liquid biopsy market in Germany. A strong emphasis on precision oncology and personalized treatment supports the adoption of liquid biopsy technologies in the country. Research institutions and academic centers are participating actively in furthering clinical validation and innovation. A strong reimbursement framework and a robust regulatory environment encourage the integration of liquid biopsy into the clinical management of patients. Growing incidence of cancer and an aging population further add to the demand. February 2023, Euformatics, a leading NGS data quality control and variant interpretation company headquartered in Finland, together with ViennaLab Diagnostics, with headquarters in Austria, and Oncompass Medicine, with headquarters in Hungary has been awarded with one of the four awarded Phase 1 contracts to research & develop the design of an economically sustainable liquid biopsy diagnostics solution based on DNA and RNA molecular profiling in cancer patients for a buyer consortium including some of the highest ranking European hospitals from Germany, France, Italy, Spain and Belgium for the OncNGS pre-commercial procurement.

India Liquid Biopsy Market

The Indian liquid biopsy market is growing at a faster rate, fueled by a rising incidence of cancer and an amplifying awareness of the availability of non-invasive diagnostics. Private diagnostics and cancer care facilities are also fueling growth. Invasive biopsies can be avoided using liquid biopsy, which is a more accessible and less invasive alternative. Initiatives by the Indian government to develop cancer screening and access to health care point toward a positive impact. While there may be hurdles such as costs and reimbursements, advancements and local development of this technology within the Indian subcontinent have made it more affordable. In February 2025, Lucence and Agilus Diagnostics have formed a strategic partnership to develop cancer testing services in India. Agilus, which is currently the largest diagnostics player in that market, would start using Lucence's advanced LiquidHALLMARK, a next-generation sequencing approach that analyzes blood for circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA), targeting 80 genes of ctDNA and 37 RNA fusions. This is a more sensitive approach than earlier sequencing methods and would help develop targeted cancer therapy based on profiling. This development will help make a preciser approach to cancer treatment available and accessible to Indians.

Saudi Arabia Liquid Biopsy Market

The Saudi Arabia liquid biopsy market is growing steadily, driven by increasing investment in the improvement of the country's healthcare infrastructure and cancer care services. The initiatives include improved mechanisms for diagnosing and effectively treating cancer, apart from facilitating the adoption of cutting-edge diagnostic solutions. The modernized hospitals and diagnostic centers in Saudi Arabia and other nations in the region are adopting liquid biopsy solutions for the purpose of analyzing treatments and precise clinical solutions related to various applications such as cancer control and prevention programs. Increased understanding and development of early-stage cancer diagnostic solutions and growth of the private healthcare sector drive the Saudi Arabia liquid biopsy market. Although in the early adoption phase, collaborations with world leaders in technology help in understanding and knowledge development related to liquid biopsy solutions in Saudi Arabia and M42's role in such developments in the UAE region. June 2025: M42 is leading in the development and delivery of solutions related to artificial intelligence and medical and clinical solutions as part of its strategy and vision for transforming the UAE and the world at large.

Market Segmentation

Product

• Kits & Reagents
• Platforms & Instruments
• Services

Application

• Cancer Therapeutic Application
• Reproductive Health
• Other Therapeutic

Circulating Biomarkers

• Circulating Tumour Cell
• Circulating Tumour DNA
• Cell-free DNA

End-User

• Hospitals
• Diagnostic Laboratories
• Point-of-care Testing
• Academic Institutes
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overview
• Key Persons
• Recent Development & Strategies
• Product Portfolio
• Financial Insights

Company Analysis:

• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories
• Thermo Fisher Scientific Inc.
• Johnson & Johnson
• Biocept Inc.
• Guardant Health
• llumina, Inc.
• Laboratory Corporation of America Holdings
• QIAGEN N.V.
• Exact Sciences Corporation